# Venous Blood Test Tubes Market

> Venous blood test tubes market: USD 2.64 billion in 2025, USD 3.80 billion by 2035, as chronic-disease draws and Asian labs add tube volume.

Publisher: Douglas Insights  
Author: Douglas Insights Research Desk  
Report code: DI-HC-10701  
Published: 2026-10-10  
Last updated: 2026-10-10  
Next review: Apr 2027  
Page: https://www.douglasinsights.com/venous-blood-test-tubes-market/

## Key figures

| Measure | Value | How it is built |
| --- | --- | --- |
| Market size · 2025 | $2.64 Bn | 15.42 billion tubes x USD 0.1712 = USD 2.64 billion |
| Forecast · 2035 | $3.80 Bn | 20.93 billion tubes x USD 0.1818 |
| Revenue CAGR · 2026-2035 | 3.72% | Multiplicative legs |
| Volume · 2035 | 20.93 billion tubes | 15.42 billion tubes growing 3.10% a year |
| Leading segment | Serum separator and clot activator tubes, 31.8% | USD 839.5 million in 2025 |
| Fastest segment | Cell-free DNA and specialty tubes, 7.45% | Liquid biopsy draws |
| Fastest region | Asia Pacific, 5.35% | USD 755.0 million to USD 1.27 billion |
| Market leader | BD, 36.9% share | 52% of USD 1.87 billion Specimen Management revenue |
| Event | IVDR applicable 26 May 2022 | Specimen receptacles deemed IVD devices |

## Key takeaways

- Venous blood test tubes are worth USD 2.64 billion in 2025 and USD 3.80 billion by 2035, growing 3.72% a year.
- 15.42 billion tubes at USD 0.1712 each make the 2025 figure; volume adds 3.10 points a year and price 0.60.
- BD leads with an estimated 36.9% share, and the top three suppliers hold 58.6% of 2025 value.
- Serum separator and clot activator tubes lead at 31.8%, while cell-free DNA and specialty tubes grow fastest at 7.45%.
- Asia Pacific grows 5.35% a year to USD 1.27 billion, overtaking North America by 2035 despite an index score of 69.

Under [Regulation (EU) 2017/746](https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32017R0746), specimen receptacles are deemed in vitro diagnostic (IVD) devices, so every evacuated tube in a European phlebotomy tray has carried IVD obligations since the rules became applicable on 26 May 2022, as the [European Commission records](https://health.ec.europa.eu/medical-devices-sector/new-regulations_en). The venous blood test tubes market covers single-use tubes, evacuated or aspiration type, that receive venous blood with or without an additive and hold it until a laboratory runs the test. Douglas Insights sizes it at USD 2.64 billion in 2025: 15.42 billion tubes at an average realised price of USD 0.1712 each. Revenue then grows 3.72% a year to USD 3.80 billion by 2035, with volume doing most of the work. The study belongs to our [in-vitro diagnostics coverage](https://www.douglasinsights.com/industry/healthcare/in-vitro-diagnostics/), and each step of the build follows the [Douglas Insights research methodology](https://www.douglasinsights.com/research-methodology/).

## Which companies supply the most venous blood test tubes, and how concentrated is the field?

Douglas Insights puts the top-three concentration in venous blood test tubes at 58.6% of 2025 value, led by BD with an estimated 36.9% share. Greiner Bio-One and Sarstedt follow, while Terumo, Streck, Hindustan Syringes and Medical Devices (HMD) and Chinese makers split the remaining 41.4%.

BD is the anchor. Its Specimen Management unit, home of the BD Vacutainer line, booked USD 1.87 billion in fiscal 2025, up 2.0% from USD 1.83 billion, with USD 981 million in the United States and USD 890 million abroad, according to [BD's fourth-quarter fiscal 2025 release](https://www.sec.gov/Archives/edgar/data/10795/000162828025049835/ex99109302025.htm). Douglas Insights estimates that tubes are 52% of that unit, about USD 973 million, because needles, holders, capillary and urine products sit in the same line. The release said fourth-quarter Vacutainer growth was partially offset by performance in China.

Greiner Bio-One, maker of VACUETTE tubes, generated about EUR 637 million in 2025 with 2,651 employees across 28 sites, per the [Greiner Bio-One financial-year statement](https://www.gbo.com/en-us/press-events/press/article/financial-year-2025). Our model assigns roughly USD 324 million of that to venous tubes, a 12.3% share. Sarstedt, owner of the S-Monovette aspiration-and-vacuum system, employs about 3,000 people, runs over 13 production sites and keeps 90% of its value chain in-house; Douglas Insights estimates its venous tube revenue at USD 248 million, or 9.4%.

Terumo sells VENOJECT II venous tubes cleared by the US Food and Drug Administration (FDA) under product code JKA. Streck holds an FDA De Novo clearance for its Cell-Free DNA BCT tube when paired with the Guardant360 CDx liquid biopsy assay, and reported sales of more than 35 million tubes worldwide when that clearance was announced. HMD lists blood collection tubes, including its Vaku 8 line, and sells through more than 4,500 authorised dealers.

| Company | Venous tube brand | Built on | Douglas Insights 2025 share |
| --- | --- | --- | --- |
| BD | BD Vacutainer | USD 1.87 billion Specimen Management unit, US plant base | 36.9% |
| Greiner Bio-One | VACUETTE | EUR 637 million division, 28 sites | 12.3% |
| Sarstedt | S-Monovette | Over 13 plants, 90% in-house value chain | 9.4% |
| Terumo | VENOJECT II | 510(k) clearance under FDA product code JKA | Not split |
| Streck | Cell-Free DNA BCT | De Novo clearance, over 35 million tubes sold | Not split |
| HMD | Vaku 8 | Over 4,500 authorised dealers | Not split |

## Where does a venous blood test tube end and capillary or culture kit begin in this study?

Venous blood test tubes are counted at 15.42 billion units in 2025, and the scope stops at the tube: needles, holders, capillary microtubes and culture bottles are excluded. Each tube is valued at the manufacturer's realised price, so distributor margins and phlebotomy labour sit outside the USD 2.64 billion figure.

Two materials appear in the count. PET plastic tubes now dominate hospital laboratories and independent clinical laboratories in high-income markets because they survive pneumatic transport and do not shatter; glass tubes survive mainly in low-cost tenders and some coagulation work. Douglas Insights counts 86.4% of 2025 units as PET plastic tubes and 13.6% as glass tubes.

End users are split four ways. Hospital laboratories draw 52.7% of tubes, independent clinical laboratories 31.5%, blood banks 6.2% for donor screening samples, and physician offices 9.6%. Blood culture bottles are covered separately in our [Blood Culture Bottle Market](https://www.douglasinsights.com/blood-culture-bottle-market/) report.

## Which additive type earns the most per venous blood test tube sold?

Serum separator and clot activator tubes lead venous blood test tube revenue with a 31.8% share, worth USD 839.5 million in 2025, because chemistry and immunoassay panels run on serum. Cell-free DNA and specialty tubes grow fastest, at 7.45% a year, as liquid biopsy volumes climb.

| Additive segment | Share 2025 | Value 2025 | CAGR 2026-2035 | Value 2035 |
| --- | --- | --- | --- | --- |
| Serum separator and clot activator tubes | 31.8% | USD 839.5 million | 3.35% | USD 1.17 billion |
| EDTA tubes | 27.4% | USD 723.3 million | 3.55% | USD 1.03 billion |
| Lithium heparin plasma tubes | 17.3% | USD 456.7 million | 3.95% | USD 672.8 million |
| Sodium citrate coagulation tubes | 11.6% | USD 306.2 million | 2.85% | USD 405.6 million |
| Sodium fluoride glucose tubes | 4.9% | USD 129.4 million | 2.15% | USD 160.1 million |
| Cell-free DNA and specialty tubes | 7.0% | USD 184.8 million | 7.45% | USD 379.1 million |

Serum separator and clot activator tubes hold 31.8% because almost every routine metabolic, lipid and hormone panel needs clotted serum, and the gel barrier adds a few cents per tube. EDTA tubes take 27.4%, or USD 723.3 million, since full blood counts and HbA1c run on whole blood. Lithium heparin plasma tubes earn USD 456.7 million at 17.3%; emergency departments favour them because plasma skips the 30-minute clotting wait.

Sodium citrate coagulation tubes carry 11.6%, about USD 306.2 million, held back by the fill-volume precision that makes them costlier to make but limits their number per draw. Sodium fluoride glucose tubes are the smallest group at 4.9%, or USD 129.4 million, and grow only 2.15% because point-of-care meters replace some laboratory glucose work.

Cell-free DNA and specialty tubes are the fastest riser: USD 184.8 million today, USD 379.1 million by 2035. A stabilising tube sells for 20 to 50 times the price of a plain EDTA tube, so a 7.0% value share comes from well under 1% of units.

## Why are venous blood test tube draw volumes still climbing at 3.10% a year?

Venous blood test tube volume rises 3.10% a year because four forces add draws: chronic-disease monitoring, Asian laboratory build-out, outpatient testing and molecular assays. Douglas Insights splits that volume leg into 1.25, 0.95, 0.50 and 0.40 percentage points, summing to the full 3.10.

Chronic-disease monitoring adds 1.25 points. Diabetes, renal and cardiometabolic patients are drawn several times a year, and each visit uses two or three venous blood test tubes. BD reports that its Vacutainer products care for 84 patients around the world every second, per its [Sumter plant release](https://news.bd.com/2025-10-03-BD-Celebrates-55-Years-of-Manufacturing-Excellence-and-Impact-in-Sumter,-S-C), which our model converts into 2.65 billion BD draws a year. At 2.3 tubes a draw, that is 6.09 billion BD tubes, the anchor for the 15.42 billion global count.

Laboratory build-out in Asia Pacific adds 0.95 points. Hospital capacity and insurance coverage in India, Indonesia and Vietnam push routine panels into populations that rarely had venous draws a decade ago. Douglas Insights expects Asia Pacific tube units to rise from 6.38 billion in 2025 to well over 9 billion by 2035, the largest absolute gain of any region.

Outpatient and retail testing adds 0.50 points. Independent clinical laboratories open patient service centres in pharmacies and clinics, and every new draw site orders a stocked tray of venous tubes. BD's US Specimen Management revenue rose 14.0% to USD 274 million in the quarter to 30 June 2026, while the nine-month US total grew 7.2% to USD 772 million, per [BD's third-quarter fiscal 2026 release](https://www.sec.gov/Archives/edgar/data/0000010795/000162828026053790/ex9916302026.htm) dated 6 August 2026.

Molecular and liquid biopsy draws add 0.40 points. Cell-free DNA tubes let a sample travel to a central sequencing laboratory without immediate plasma separation, and Streck's sale of more than 35 million such tubes shows that volume is real, not speculative. Each added oncology or prenatal screening draw uses one specialty tube worth several dollars.

BD is also adding capacity: it invested more than USD 90 million in its Sumter, South Carolina site since fiscal 2021 and plans about USD 30 million more in fiscal 2026. Suppliers do not fund plants for flat venous tube volume. Douglas Insights reckons the four drivers together lift global tube output from 15.42 billion in 2025 to 20.93 billion in 2035, an extra 5.51 billion venous blood test tubes a year by the end of the forecast.

## Which headwinds keep venous blood test tube revenue below unit growth?

Three headwinds hold venous blood test tube revenue growth to 3.72% against much faster draw growth in Asia: Chinese procurement tenders, test-utilisation stewardship and IVDR certification cost. Together they remove about 0.90 points from the base case, and the legs already net them out.

Chinese volume-based procurement removes 0.45 points from the price leg. BD lists China's volume-based procurement tender process among factors that can reduce demand or force lower prices, and its International Specimen Management revenue grew just 0.9% in fiscal 2025 to USD 890 million while US sales rose 3.0%.

Test-utilisation stewardship removes 0.30 points from volume. Hospitals cut duplicate panels and adopt smaller-volume venous tubes to reduce iatrogenic blood loss, which trims the tubes per draw from about 2.4 toward 2.2 in North America and Europe.

IVDR certification removes 0.15 points. Under [Regulation (EU) 2024/1860](https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32024R1860) of 13 June 2024, class B devices and class A devices placed on the market in sterile condition must meet notified-body requirements by 31 December 2029. Smaller tube makers face audit and technical-file costs that a 0.1712-dollar product struggles to absorb.

## Where do venous blood test tubes sell, region by region?

North America leads venous blood test tube revenue with USD 902.8 million in 2025, a 34.2% share, because its realised price per tube is the highest. Asia Pacific grows fastest, at 5.35% a year, as hospital laboratories multiply and draws per head rise.

North America reaches USD 1.21 billion by 2035 at 3.00% a year, supported by BD's US manufacturing base and the shift toward retail draw sites. Europe holds USD 736.5 million, or 27.9%, and grows only 2.55% a year because draw volumes are mature and tenders cap prices; it reaches USD 947.4 million in 2035.

Asia Pacific starts at USD 755.0 million, a 28.6% share, and passes North America to reach USD 1.27 billion by 2035. Chinese tender prices keep its average venous tube price near USD 0.118, but its unit count grows faster than anywhere else. Latin America is worth USD 147.8 million and grows 4.10% to USD 220.9 million, led by Brazilian and Mexican private laboratories.

The Middle East and Africa is the wildcard: USD 97.8 million in 2025, rising 4.38% a year to USD 150.2 million. Gulf hospital programmes buy premium venous blood test tubes, while African volumes depend on donor-funded HIV and tuberculosis testing that can swing year to year.

## How much does a laboratory pay per evacuated venous blood test tube?

A laboratory pays between USD 0.04 and USD 0.35 for a routine venous blood test tube in 2025, and Douglas Insights calculates the blended realised price at USD 0.1712. Specialty stabilising tubes sit far above that band, at USD 3.50 to USD 8.00 each.

Commodity plain and EDTA venous tubes from Chinese and Indian makers clear at USD 0.04 to USD 0.08 ex-works. European branded tubes sold into hospital tenders realise USD 0.12 to USD 0.22, while US group purchasing contracts for serum separator and plasma tubes run from USD 0.18 to USD 0.35. These bands are Douglas Insights estimates from the regional price per tube implied by our model, not list prices.

Average price rises 0.60% a year to USD 0.1818 by 2035. The mix shift toward cell-free DNA tubes adds price; Chinese tenders and private-label PET tubes subtract it.

## How do IVDR rules and FDA classification govern venous blood test tubes?

Venous blood test tubes are regulated diagnostics on both sides of the Atlantic: the EU treats them as IVD specimen receptacles, and the FDA classes them as class II devices under 21 CFR 862.1675. Compliance cost therefore scales with the number of additive variants a maker sells.

In the EU, Regulation (EU) 2017/746 states that specimen receptacles shall be deemed in vitro diagnostic medical devices, whether vacuum-type or not. The 2024 amendment sets 31 December 2029 for class B and sterile class A legacy devices to complete notified-body certification, which matters for venous tube makers selling sterile-interior lines.

In the United States, blood collection tubes sit under FDA product code JKA, regulation 862.1675, as class II devices that reach the market through 510(k) clearance; Terumo's VENOJECT II tubes are one cleared example. Stabilising tubes that claim a specific assay pairing, such as Streck's, needed a De Novo route instead.

## Glass or PET plastic: how is the venous tube material mix shifting?

PET plastic tubes account for 86.4% of venous blood test tube units in 2025, and Douglas Insights projects 91.2% by 2035 as glass tubes fade from hospital laboratories. Breakage, weight and pneumatic-tube transport all favour plastic.

Glass tubes keep 13.6% of units today, mostly in low-price tenders and in citrate work where some laboratories still prefer glass surface chemistry. Blood banks and physician offices adopted PET plastic tubes early because shipping glass from satellite sites raised breakage rates.

## What did BD's Waters transaction change for venous blood test tube supply?

BD kept its USD 1.87 billion Specimen Management unit, maker of Vacutainer venous blood test tubes, when it spun off Biosciences and Diagnostic Solutions into Waters on 9 February 2026. BD's [completion release](https://www.sec.gov/Archives/edgar/data/10795/000119312526042827/d104936dex991.htm) describes the remaining company as a pure-play medical technology group, and the tube line now sits inside its Medical Essentials segment.

The deal valued the divested business at USD 18.8 billion and gave BD USD 4 billion in cash. For tube buyers the practical point is focus: Medical Essentials booked USD 1.68 billion in the quarter to 30 June 2026, and Specimen Management's USD 511 million was up 8.7% from USD 470 million. Laboratory automation suppliers that sort and decap tubes are covered in our [Clinical Lab Automation Market](https://www.douglasinsights.com/clinical-lab-automation-market/) study.

## What if Chinese tenders or liquid biopsy move faster: venous blood test tube scenarios to 2035?

Venous blood test tube revenue lands at USD 3.80 billion by 2035 in the base case, USD 3.35 billion in the slower case and USD 4.32 billion in the faster case. Volume growth is the swing factor, and the 3.72% base rate sits at the low end of published forecasts.

The base case runs 3.10% volume and 0.60% price. The slower case cuts volume to 2.20% and price to 0.20%, which is what wider Chinese tender pricing and tighter test stewardship in Europe would produce. The faster case lifts volume to 4.00% and price to 1.00%, driven by cell-free DNA screening and Asian laboratory build-out.

Sensitivity is asymmetric. Adding one point to annual tube growth lifts the 2035 total by USD 385.5 million; removing one point cuts it by USD 353.2 million. Published forecasts for blood and venous collection tubes span about 3.6% to 7.2% a year, and our figure sits near the bottom because it values tubes only, at realised prices.

The dated anchors move with the scenarios. BD's 8.7% Specimen Management growth in the quarter reported on 6 August 2026 fits the faster case for the United States, while the 31 December 2029 IVDR deadline is the main European test for the slower case.

## Douglas Exclusive: the Venous Tube Price-Intensity Index

The Venous Tube Price-Intensity Index is a Douglas Insights model, not an official statistic. It is built from 9 sourced inputs, including BD's 84-patients-a-second figure, BD Specimen Management revenue for five reporting periods, Greiner Bio-One's EUR 637 million and Streck's 35 million tubes, plus 4 stated Douglas Insights assumptions.

The index divides each region's modelled venous blood test tube revenue by its modelled tube count and scores the result against the global average price of USD 0.1712, set to 100.

| Region | Tubes 2025 (billion) | Price per tube (USD) | Index |
| --- | --- | --- | --- |
| North America | 3.86 | 0.234 | 137 |
| Europe | 3.58 | 0.206 | 120 |
| Asia Pacific | 6.38 | 0.118 | 69 |
| Latin America | 0.97 | 0.152 | 89 |
| Middle East and Africa | 0.63 | 0.155 | 91 |

The finding is stark. Asia Pacific draws 41.4% of the world's venous tubes but earns 28.6% of the value, scoring 69, while North America scores 137. Every point of unit share that moves east lowers the global average price, which is why the price leg stays at 0.60% even as specialty tubes gain.

## How we count 15.42 billion venous blood test tubes and check the total?

Douglas Insights counts 15.42 billion venous blood test tubes in 2025 across 5 regions and 6 additive segments, from 9 sourced inputs and 4 assumptions. Our arithmetic is direct: 15.42 billion tubes times USD 0.1712 equals USD 2.64 billion.

Step one: 84 BD patients a second times 31,536,000 seconds gives 2.65 billion draws. Step two: 2.3 tubes per draw gives 6.09 billion BD tubes. Step three: a 39.5% BD unit share gives 15.42 billion global tubes. Cross-check one: tubes at 52% of BD's USD 1.87 billion Specimen Management revenue give USD 973 million, a 36.9% value share, within 2.6 points of the unit share. Cross-check two: published 2025 estimates for broader blood collection tubes run to USD 3.6 billion, so a tubes-only USD 2.64 billion figure is consistent.

Douglas Insights analysts drafted this study with AI assistance and checked every sourced figure against the linked primary pages. Related purification steps after the draw are covered in our [Magnetic Bead-based Nucleic Acid Extraction Market](https://www.douglasinsights.com/magnetic-bead-based-nucleic-acid-extraction-market/) report.

## Which end users draw the most venous blood test tubes?

Hospital laboratories draw 52.7% of venous blood test tubes, about 8.13 billion units in 2025, because inpatients and emergency patients are drawn daily. Independent clinical laboratories follow at 31.5%, and they grow fastest at about 4.2% a year in units.

Physician offices use 9.6% of tubes, roughly 1.48 billion, mostly for samples sent to reference laboratories. Blood banks take 6.2%, about 0.96 billion tubes, for donor screening and typing, a share tied to collection volumes rather than disease testing.

## Market by segment

| Segment | Share | Value |
| --- | --- | --- |
| Serum separator and clot activator tubes | 31.8% | $839.5 Mn |
| EDTA tubes | 27.4% | $723.3 Mn |
| Lithium heparin plasma tubes | 17.3% | $456.7 Mn |
| Sodium citrate coagulation tubes | 11.6% | $306.2 Mn |
| Sodium fluoride glucose tubes | 4.9% | $129.4 Mn |
| Cell-free DNA and specialty tubes | 7% | $184.8 Mn |

## Market by region (USD million)

| Region | 2025 | 2026 | 2035 | CAGR 2026-2035 |
| --- | --- | --- | --- | --- |
| Global | 2,639.9 | 2,738.1 | 3,803.2 | 3.72% |
| North America | 902.8 | 929.9 | 1,213.3 | 3% |
| Europe | 736.5 | 755.3 | 947.4 | 2.55% |
| Asia Pacific | 755 | 795.4 | 1,271.4 | 5.35% |
| Latin America | 147.8 | 153.9 | 220.9 | 4.1% |
| Middle East and Africa | 97.8 | 102.1 | 150.2 | 4.38% |

## Dataset

| Series | Value | Unit |
| --- | --- | --- |
| Market size 2025 | 2,639.9 | USD million |
| Market size 2035 | 3,803.2 | USD million |
| Revenue CAGR 2026-2035 | 3.72 | percent |
| Volume CAGR 2026-2035 | 3.1 | percent |
| Price per tube CAGR 2026-2035 | 0.6 | percent |

## Frequently asked questions

### What is a venous blood test tube worth to its maker on average?

USD 0.1712 per tube in 2025, the blended realised price across 15.42 billion tubes, rising to USD 0.1818 by 2035.

### What revenue do venous blood test tubes generate in 2025 and 2035?

USD 2.64 billion in 2025, rising to USD 3.80 billion by 2035 at 3.72% a year, with 3.10 points from volume and 0.60 from price.

### How much of the venous tube market does BD hold?

36.9% share in 2025 by Douglas Insights estimate, about USD 973 million, taken as 52% of BD's USD 1.87 billion Specimen Management revenue.

### Which additive tube earns the most revenue?

31.8% of 2025 value goes to serum separator and clot activator tubes, USD 839.5 million, because chemistry and immunoassay panels run on serum.

### Why do cell-free DNA tubes outgrow routine venous tubes?

7.45% a year is the cell-free DNA and specialty tube growth rate, because liquid biopsy samples must travel to central laboratories without immediate plasma separation.

### Which region draws the most tubes but earns the least per tube?

41.4% of global venous tube units come from Asia Pacific, which scores 69 on the Douglas Insights price-intensity index against 137 for North America.

### When must sterile class A venous tubes meet IVDR notified-body rules?

31 December 2029 is the deadline Regulation (EU) 2024/1860 sets for class B devices and class A devices placed on the market in sterile condition.

### What happens to the 2035 figure if tube growth shifts by one point?

USD 385.5 million is added by one extra point of annual tube growth, while one point less removes USD 353.2 million from the USD 3.80 billion base.

## Sources

- [EUR-Lex, Regulation (EU) 2017/746 on in vitro diagnostic medical devices](https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32017R0746)
- [European Commission, New regulations: IVDR applicable 26 May 2022](https://health.ec.europa.eu/medical-devices-sector/new-regulations_en)
- [EUR-Lex, Regulation (EU) 2024/1860 amending IVDR transitional provisions](https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32024R1860)
- [BD via SEC EDGAR, BD fourth quarter and full year fiscal 2025 results (Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/10795/000162828025049835/ex99109302025.htm)
- [BD via SEC EDGAR, BD third quarter fiscal 2026 results (Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/0000010795/000162828026053790/ex9916302026.htm)
- [BD via SEC EDGAR, BD completes combination of Biosciences and Diagnostic Solutions with Waters](https://www.sec.gov/Archives/edgar/data/10795/000119312526042827/d104936dex991.htm)
- [BD, BD celebrates 55 years of manufacturing in Sumter, S.C.](https://news.bd.com/2025-10-03-BD-Celebrates-55-Years-of-Manufacturing-Excellence-and-Impact-in-Sumter,-S-C)
- [US FDA, 510(k) K900309 VENOJECT II blood collection tubes](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K900309)
- [US FDA, Product classification JKA, 21 CFR 862.1675](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm?id=JKA)
- [Greiner Bio-One, Financial year 2025](https://www.gbo.com/en-us/press-events/press/article/financial-year-2025)
- [Sarstedt, About us](https://www.sarstedt.com/en/company/about-us/)
- [Streck, Cell-Free DNA BCT receives U.S. FDA De Novo clearance](https://www.streck.com/?p=5942)
- [Hindustan Syringes and Medical Devices, About HMD](https://hmdhealthcare.com/about-hmd/)

## How to cite

Douglas Insights, "Venous Blood Test Tubes Market", DI-HC-10701, updated 2026-10-10, https://www.douglasinsights.com/venous-blood-test-tubes-market/